Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings in Brief: Med-Design Corporation

This article was originally published in The Gray Sheet

Executive Summary

Med-Design Corporation: Files registration statement with the Securities and Exchange Commission for an initial public offering of 1.5 mil. shares of common stock, expected to be sold for between $6.50 and $7 per share. Based in Philadelphia, Med-Design is developing safety devices intended to lower the incidence of accidental needlesticks. The firm's first three products are a safety syringe, a safety phlebotomy set, and a safety catheter. Each product features a retractable needle that is rendered risk-free once therapy is delivered. The 11-employee company anticipates that FDA will determine all three products to be Class II devices and that 510(k)s for all three will be filed by the end of 1995.

You may also be interested in...



Sanofi CEO Hudson Delivers An Ambitious Turnaround Agenda

CEO Paul Hudson came to Sanofi's capital markets day with big news and key messages for investors about the company's future business model. 

Sanofi Has The Fire Power For Deals, CEO Hudson Says

The company is looking at deals in the $2bn to $5bn range, CEO Paul Hudson told investors, but premiums for assets are high and Sanofi is looking at earlier-stage opportunities as a result.

Corindus Envisions Network Of CorPath Robots For Remote Neurovascular And Coronary Interventions

The physician who led the first first-in-human robotic-assisted neurovascular intervention with Corindus’ CorPath GRX system believes the technology could revolutionize neurovascular intervention by allowing a centralized interventional team to remotely treat patients.

UsernamePublicRestriction

Register

MT004050

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel